10-Q: Nu-Med Plus Reports Continued Losses in Q1 2025, Citing Need for Additional Funding

Nu-Med Plus, a medical device company, reported no revenue and a net loss of $19,933 for the quarter ended March 31, 2025, highlighting the company's reliance on external funding to continue operations and product development.

Summary

• Nu-Med Plus, Inc. reported its financial results for the quarter ended March 31, 2025.
• The company is focused on developing and marketing medical devices utilizing nitric oxide.
• For the quarter, Nu-Med Plus reported no revenue, consistent with the same period in 2024.
• Operating expenses were $18,700, a slight decrease from $20,579 in the prior year.
• The company's net loss for the quarter was $19,933, compared to a net loss of $21,826 in the first quarter of 2024.
• Basic and diluted loss per share remained at $0.00.
• As of March 31, 2025, the company's assets totaled $5,173, while liabilities amounted to $240,202.
• The company has a working capital deficiency of $235,029.
• Nu-Med Plus acknowledges that its current funds are insufficient to execute its business plan and requires additional funding of approximately $1,200,000 over the next 12 months.
• The company's ability to continue as a going concern is dependent on obtaining further financing.
• The company's products are still in the development stage, and no revenue is anticipated in the foreseeable future.
• The company's disclosure controls and procedures were not effective to provide reasonable assurance that information is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the lack of revenue, significant losses, reliance on external funding, and concerns about the company's ability to continue as a going concern. The ineffective disclosure controls and procedures further contribute to the negative sentiment.

Positives

• Operating expenses decreased slightly from $20,579 to $18,700 compared to the same period last year, primarily due to a decrease in professional and consulting fees.

Negatives

• The company reported no revenue for the quarter.
• The company has a significant working capital deficiency of $235,029.
• The company's current assets are only $5,173, while its liabilities are $240,202.
• The company's disclosure controls and procedures were not effective.

Risks

• The company's ability to continue as a going concern is dependent on obtaining further financing.
• The company's products are still in the development stage, and no revenue is anticipated in the foreseeable future.
• The company acknowledges that its current funds are insufficient to execute its business plan.
• The company's disclosure controls and procedures were not effective.
• The company relies on loans from shareholders or sale of stock to cover expenses.

Future Outlook

The company anticipates needing $1,200,000 in additional financing for the next twelve months to cover corporate overhead and product development. The company will have to continue to rely on outside funding to support its operations and product development and testing efforts.

Management Comments

• Management acknowledges that the funds on hand as of March 31, 2025, will not be sufficient to enable it to execute its business plan.
• Management believes that with the further refinement of our formulation, we can make and filter medical grade nitric oxide gas with minimal amounts of nitrogen dioxide, and that this process can produce medical grade nitric oxide gas in ample quantities for any current or prospective use and hopefully at a price less than that of all currently available technologies.

Industry Context

The company is targeting the nitric oxide delivery market, where the current market leader, Inomax, faces no price competition. Nu-Med Plus aims to offer a lower-cost alternative through on-site generated nitric oxide.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Without revenue, it is difficult to compare Nu-Med Plus to other medical device companies.
• The company's reliance on external funding is not uncommon for early-stage medical device companies, but the extent of the need raises concerns.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and reliance on external funding.
• Employees' job security is uncertain due to the company's financial situation.
• The company's ability to develop and commercialize its products is dependent on securing additional funding.

Next Steps

• The company needs to secure additional funding to continue operations and product development.
• The company is working to secure funding that will enable it to submit the hospital unit for FDA approval.
• The company needs to refine its nitric oxide formulation and packaging.
• The company needs to improve its disclosure controls and procedures.

Key Dates

Keywords

Nitric Oxide, Medical Devices, Funding, Liquidity, Financial Results, Quarterly Report, NU-MED PLUS